Karin Vanderkerken
Overview
Explore the profile of Karin Vanderkerken including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
4067
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hose D, Ray S, Rossler S, Thormann U, Schnettler R, de Veirman K, et al.
J Hematol Oncol
. 2025 Jan;
18(1):11.
PMID: 39856743
No abstract available.
2.
Hose D, Ray S, Rossler S, Thormann U, Schnettler R, de Veirman K, et al.
J Hematol Oncol
. 2024 Dec;
17(1):128.
PMID: 39695697
Background: Accumulation of malignant plasma cells in the bone marrow causes lytic bone lesions in 80% of multiple myeloma patients. Frequently fracturing, they are challenging to treat surgically. Myeloma cells...
3.
Verheye E, Kancheva D, Satilmis H, Vandewalle N, Fan R, Bardet P, et al.
J Hematol Oncol
. 2024 Nov;
17(1):107.
PMID: 39511632
Background: The long-term effectiveness of immunotherapies against Multiple Myeloma (MM) remains elusive, demonstrated by the inevitable relapse in patients. This underscores the urgent need for an in-depth analysis of the...
4.
Vandewalle N, De Beule N, De Becker A, de Bruyne E, Menu E, Vanderkerken K, et al.
Exp Hematol Oncol
. 2024 Oct;
13(1):99.
PMID: 39367387
Until recently, treatment options for patients diagnosed with Acute Myeloid Leukemia (AML) were limited and predominantly relied on various combinations, dosages, or schedules of traditional chemotherapeutic agents. Patients with advanced...
5.
Van der Vreken A, Vanderkerken K, de Bruyne E, de Veirman K, Breckpot K, Menu E
Exp Hematol Oncol
. 2024 Jul;
13(1):66.
PMID: 38987856
CAR T cells are widely applied for relapsed hematological cancer patients. With six approved cell therapies, for Multiple Myeloma and other B-cell malignancies, new insights emerge. Profound evidence shows that...
6.
Wang Y, Vandewalle N, de Veirman K, Vanderkerken K, Menu E, de Bruyne E
Cell Commun Signal
. 2024 Jun;
22(1):320.
PMID: 38862983
Multiple Myeloma (MM), a cancer of terminally differentiated plasma cells, is the second most prevalent hematological malignancy and is incurable due to the inevitable development of drug resistance. Intense protein...
7.
Vandewalle N, Satilmis H, Verheye E, Fan R, Wang Y, De Groof T, et al.
Theranostics
. 2024 May;
14(7):2656-2674.
PMID: 38773967
AXL expression has been identified as a prognostic factor in acute myeloid leukemia (AML) and is detectable in approximately 50% of AML patients. In this study, we developed AXL-specific single...
8.
Fan R, Satilmis H, Vandewalle N, Verheye E, de Bruyne E, Menu E, et al.
Blood Cancer J
. 2023 Dec;
13(1):188.
PMID: 38110349
Acute Myeloid Leukemia (AML) is a heterogeneous disease with limited treatment options and a high demand for novel targeted therapies. Since myeloid-related protein S100A9 is abundantly expressed in AML, we...
9.
Emde-Rajaratnam M, Beck S, Benes V, Salwender H, Bertsch U, Scheid C, et al.
Front Immunol
. 2023 Nov;
14:1286700.
PMID: 38035078
Background: Immunotherapeutic targets in multiple myeloma (MM) have variable expression height and are partly expressed in subfractions of patients only. With increasing numbers of available compounds, strategies for appropriate choice...
10.
Wang Y, Muylaert C, Wyns A, Vlummens P, de Veirman K, Vanderkerken K, et al.
Haematologica
. 2023 Jul;
109(1):256-271.
PMID: 37470139
Multiple myeloma (MM) is the second most prevalent hematologic malignancy and is incurable because of the inevitable development of drug resistance. Methionine adenosyltransferase 2α (MAT2A) is the primary producer of...